<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">PONE-D-12-19300</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0049134</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Genetics</subject>
            <subj-group>
              <subject>Human genetics</subject>
              <subj-group>
                <subject>Genetic association studies</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Population genetics</subject>
              <subj-group>
                <subject>Genetic polymorphism</subject>
              </subj-group>
            </subj-group>
            <subj-group>
              <subject>Genetics of disease</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Clinical research design</subject>
            <subj-group>
              <subject>Meta-analyses</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Epidemiology</subject>
            <subj-group>
              <subject>Genetic epidemiology</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Oncology</subject>
            <subj-group>
              <subject>Cancer risk factors</subject>
              <subj-group>
                <subject>Genetic causes of cancer</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Genetics and Genomics</subject>
          <subject>Public Health and Epidemiology</subject>
          <subject>Oncology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Meta-Analysis of Cytochrome P-450 2C9 Polymorphism and Colorectal Cancer Risk</article-title>
        <alt-title alt-title-type="running-head">CYP2C9 and Colorectal Cancer Susceptibility</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Liang</surname>
            <given-names>Shuo</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
          <name name-style="western">
            <surname>Hu</surname>
            <given-names>Jingsong</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Cao</surname>
            <given-names>Weijun</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Cai</surname>
            <given-names>Sanjun</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>Department of Respiratory, Pulmonary Hospital of Shanghai, Tongji University School of Medicine, Shanghai, People’s Republic of China</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>Department of Colorectal Cancer, Shanghai Cancer Center, Fudan University School of Medicine, Shanghai, People’s Republic of China</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Szecsi</surname>
            <given-names>Pal Bela</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>Gentofte University Hospital, Denmark</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">Weijun_Cao@163.com</email> (WC); <email xlink:type="simple">Sanjun_Cai@163.com</email> (SC)</corresp>
        <fn fn-type="conflict">
          <p>The authors have declared that no competing interests exist.</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: WjC SjC. Performed the experiments: SL JsH. Analyzed the data: SL JsH. Contributed reagents/materials/analysis tools: SL JsH. Wrote the paper: WjC SjC.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>7</day>
        <month>11</month>
        <year>2012</year>
      </pub-date>
      <volume>7</volume>
      <issue>11</issue>
      <elocation-id>e49134</elocation-id>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>7</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>10</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Liang et al</copyright-holder>
        <license xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes which play a central role in activating and detoxifying many carcinogens and endogenous compounds thought to be involved in the development of colorectal cancer (CRC). In the past decade, the relationship between CYP2C9 common polymorphisms (R144C and I359L) and CRC has been reported in various ethnic groups; however, these studies have yielded contradictory results. To investigate this inconsistency, we performed this meta-analysis.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Databases including Pubmed, EMBASE, Web of Science and China National Knowledge Infrastructure (CNKI) were searched to find relevant studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>A total of 13 articles involving 9,463 cases and 11,416 controls were included. Overall, the summary odds ratio of CRC was 0.98 (95% CI: 0.89−1.06) and 0.99 (95% CI: 0.87−1.14) for CYP2C9 144C and 359L alleles, respectively. No significant results were observed using dominant or recessive genetic model for these polymorphisms. In the stratified analyses according to ethnicity and sex, no evidence of any gene-disease association was obtained.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This meta-analysis suggests that the CYP2C9 may not be associated with colorectal cancer development.</p>
        </sec>
      </abstract>
      <funding-group>
        <funding-statement>This work was supported by the Natural Science Foundation of Shanghai (10ZR1425000), Doctoral Fund of Ministry of Education of China (20100072120060), key projects of Shanghai Municipal Health Bureau (2010006), the Science and Technology Commission of Shanghai Municipality (0852nm05600, 09411951500), National Science Foundation of China (30971323) and Shanghai Subject Chief Scientist (08XD14034). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
      </funding-group>
      <counts>
        <page-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Colorectal cancer (CRC), second only to lung cancer, is a major cause of cancer death in the western world <xref ref-type="bibr" rid="pone.0049134-Center1">[1]</xref>. Despite much investigation, the causes are not yet fully understood. The marked regional differences of CRC incidence rates implicate the combined influence of genetic predisposition and local environmental factors such as local carcinogen exposure and diet <xref ref-type="bibr" rid="pone.0049134-Gertig1">[2]</xref>–<xref ref-type="bibr" rid="pone.0049134-Lafuente1">[4]</xref>.</p>
      <p>Diverse xenobiotic-metabolizing enzymes that are capable of activating carcinogens and mutagens are expressed in human intestinal epithelium <xref ref-type="bibr" rid="pone.0049134-Windmill1">[5]</xref>, <xref ref-type="bibr" rid="pone.0049134-Ilett1">[6]</xref>. Among them, cytochrome P450 (CYP) enzymes play a key role in the metabolism of xenobiotics. The CYP2C enzyme subfamily accounts for about 20% of the total CYP enzymes in human liver, CYP2C9 being the most abundant <xref ref-type="bibr" rid="pone.0049134-Goldstein1">[7]</xref>, <xref ref-type="bibr" rid="pone.0049134-Inoue1">[8]</xref>. CYP2C9 is involved in both the activation of dietary carcinogens and mutagens, liver metabolism and local metabolism in intestinal epithelium may occur. Since CRC risk is epidemiologically linked to dietary habits, CYP2C9 gene may be a good candidate for genetics studies on CRC. Several important single nucleotide polymorphisms have been identified in the CYP2C9 gene. Two coding-region CYP2C9 variants (Arg144Cys and Ile359Leu) encode three common polymorphisms: the wild-type CYP2C9*1 allele, and two variant *2, and *3 alleles identified in Caucasians <xref ref-type="bibr" rid="pone.0049134-Tang1">[9]</xref>–<xref ref-type="bibr" rid="pone.0049134-Sandberg1">[12]</xref>. In vitro analyses have shown substantial variation in CYP2C9 metabolic capacity with the variant *2 and *3 alleles associated with 30% and 80% lower enzymatic activity, respectively, when compared with the wild-type *1 allele <xref ref-type="bibr" rid="pone.0049134-Takanashi1">[13]</xref>, <xref ref-type="bibr" rid="pone.0049134-Crespi1">[14]</xref>.</p>
      <p>Despite the biological plausibility of CYP2C9 functional polymorphisms as a modulator of CRC susceptibility, previously inconsistent results have appeared in the literature. Published studies have generally been restricted in terms of sample size and ethnic diversity, and individual studies may have insufficient power to achieve a comprehensive and reliable conclusion. We therefore performed a meta-analysis of the published studies to clarify this inconsistency and to establish a comprehensive picture of the relationship between CYP2C9 and CRC.</p>
    </sec>
    <sec id="s2" sec-type="materials|methods">
      <title>Materials and Methods</title>
      <sec id="s2a">
        <title>Literature Search Strategy</title>
        <p>Genetic association studies published before the end of Apr. 2012 on CRC and polymorphisms within CYP2C9 gene were identified through a search of PubMed, Web of Science, EMBASE and CNKI (Chinese National Knowledge Infrastructure) without language restrictions. Search term combinations were keywords relating to the CYP2C9 gene (e.g., “cytochrome p450 2C9”, “cytochrome p450 IIC9”, and “CYP2C9”) in combination with words related to CRC (e.g., “colorectal”, “colon”, “rectal” combined with “cancer” or “carcinoma” or “tumor” or “neoplasms”) and polymorphism or variation. The search was supplemented by reviews of reference lists for all relevant studies and review articles. The major inclusion criteria were (a) original papers containing independent data, (b) case–control or cohort studies and (c) genotype distribution information or odds ratio (OR) with its 95% confidence interval (CI) and P-value. The major reasons for exclusion of studies were (a) overlapping data and (b) case-only studies, family-based studies and review articles.</p>
      </sec>
      <sec id="s2b">
        <title>Data Extraction</title>
        <p>For each study, the following data were extracted independently by two authors: first author’s surname, year of publication, diagnosis criterion, age, sex, ethnicity, Hardy–Weinberg equilibrium (HWE) status, genotyping method, source of control, total number of cases and controls and genotype frequency in cases and controls. The results were compared, and disagreements were discussed among all authors and resolved with consensus.</p>
      </sec>
      <sec id="s2c">
        <title>Statistical Methods</title>
        <p>Odds ratio (OR) with 95% confidence intervals (CIs) was used to assess the strength of association between the CYP2C9 gene polymorphism and CRC risk. The per-allele OR of the risk allele of these polymorphisms mentioned above was compared between cases and controls. Additional pooled estimates were also given with corresponding results under dominant and recessive genetic models. Cochran’s chi-square-based Q statistic test was performed in order to assess possible heterogeneity between the individual studies and thus to ensure that each group of studies was suitable for meta-analysis. ORs were pooled according to the method of DerSimonian and Laird that takes into account the variation between studies, and 95% CI were constructed using Woolf’s method <xref ref-type="bibr" rid="pone.0049134-DerSimonian1">[15]</xref>, <xref ref-type="bibr" rid="pone.0049134-Woolf1">[16]</xref>. The Z test was used to determine the significance of the pooled OR. Sensitivity analyses were performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set to the overall OR. Publication bias was assessed using Egger’s test <xref ref-type="bibr" rid="pone.0049134-Egger1">[17]</xref> and Begg’s funnel plots <xref ref-type="bibr" rid="pone.0049134-Begg1">[18]</xref>. All P values are two-sided, and P&lt;0.05 were considered statistically significant. Statistical analyses were done with Stata (version 10.0).</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <sec id="s3a">
        <title>Characteristics of Studies</title>
        <p>The combined search yielded 93 references. Study selection process was shown in <xref ref-type="fig" rid="pone-0049134-g001">Figure 1</xref>. Finally, a total of 14 studies from 13 articles were finally included with 9,463 patients and 11,416 controls <xref ref-type="bibr" rid="pone.0049134-Martinez1">[19]</xref>–<xref ref-type="bibr" rid="pone.0049134-Sainz1">[31]</xref>. For the R144C polymorphism (rs1799853), 13 studies were available, including a total of 9,154 cases and 10,900 controls. For the I359L polymorphism (rs1057910), 13 studies involved a total of 7,701 cases and 9,287 controls. These three polymorphisms were found to occur in frequencies consistent with HWE in the control populations of the vast majority of the published studies. Of the cases, 96% were Caucasian, 4% were other ethnic origins. The detailed characteristics of the studies included in this meta-analysis are shown in <xref ref-type="table" rid="pone-0049134-t001">Table 1</xref>.</p>
        <fig id="pone-0049134-g001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0049134.g001</object-id>
          <label>Figure 1</label>
          <caption>
            <title>The flow chart of the included studies.</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0049134.g001" position="float" xlink:type="simple"/>
        </fig>
        <table-wrap id="pone-0049134-t001" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0049134.t001</object-id>
          <label>Table 1</label>
          <caption>
            <title>Characteristics of the studies included in the meta-analysis.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0049134-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0049134.t001" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Study</td>
                  <td align="left" rowspan="1" colspan="1">Year</td>
                  <td align="left" rowspan="1" colspan="1">Ethnicity</td>
                  <td align="left" rowspan="1" colspan="1">Case</td>
                  <td align="left" rowspan="1" colspan="1">Control</td>
                  <td align="left" rowspan="1" colspan="1">No. of case/control</td>
                  <td align="left" rowspan="1" colspan="1">Gender distributionin cases/controls(male %)</td>
                  <td align="left" rowspan="1" colspan="1">Control source</td>
                  <td align="left" rowspan="1" colspan="1">Genotyping method</td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Martínez <xref ref-type="bibr" rid="pone.0049134-Martinez1">[19]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2001</td>
                  <td align="left" rowspan="1" colspan="1">Spanish</td>
                  <td align="left" rowspan="1" colspan="1">Histology confirmed</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">110/123</td>
                  <td align="left" rowspan="1" colspan="1">53.0/53.0</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">RFLP</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Chan <xref ref-type="bibr" rid="pone.0049134-Chan1">[20]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2004</td>
                  <td align="left" rowspan="1" colspan="1">American</td>
                  <td align="left" rowspan="1" colspan="1">Histology confirmed</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">339/350</td>
                  <td align="left" rowspan="1" colspan="1">0/0</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">Taqman</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Tranah <xref ref-type="bibr" rid="pone.0049134-Tranah1">[21]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2005</td>
                  <td align="left" rowspan="1" colspan="1">American</td>
                  <td align="left" rowspan="1" colspan="1">CRC patients</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">416/825</td>
                  <td align="left" rowspan="1" colspan="1">0/0</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">Taqman</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Landi <xref ref-type="bibr" rid="pone.0049134-Landi1">[22]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2005</td>
                  <td align="left" rowspan="1" colspan="1">Spanish</td>
                  <td align="left" rowspan="1" colspan="1">CRC patients</td>
                  <td align="left" rowspan="1" colspan="1">Cancer free</td>
                  <td align="left" rowspan="1" colspan="1">364/324</td>
                  <td align="left" rowspan="1" colspan="1">NA/NA</td>
                  <td align="left" rowspan="1" colspan="1">HB</td>
                  <td align="left" rowspan="1" colspan="1">Sequencing</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">McGreavey <xref ref-type="bibr" rid="pone.0049134-McGreavey1">[23]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2005</td>
                  <td align="left" rowspan="1" colspan="1">British</td>
                  <td align="left" rowspan="1" colspan="1">ICD-9</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">490/592</td>
                  <td align="left" rowspan="1" colspan="1">61.0/54.0</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">Taqman</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Samowitz <xref ref-type="bibr" rid="pone.0049134-Samowitz1">[24]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2006</td>
                  <td align="left" rowspan="1" colspan="1">American</td>
                  <td align="left" rowspan="1" colspan="1">ICD-9</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">2295/2903</td>
                  <td align="left" rowspan="1" colspan="1">57.1/54.6</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">RFLP, TaqMan</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Liao <xref ref-type="bibr" rid="pone.0049134-Liao1">[25]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2007</td>
                  <td align="left" rowspan="1" colspan="1">Chinese</td>
                  <td align="left" rowspan="1" colspan="1">CRC patients</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">284/483</td>
                  <td align="left" rowspan="1" colspan="1">54.5/53.6</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">Sequencing</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Küry <xref ref-type="bibr" rid="pone.0049134-Kry1">[26]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2007</td>
                  <td align="left" rowspan="1" colspan="1">French</td>
                  <td align="left" rowspan="1" colspan="1">CRC patients</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">1013/1118</td>
                  <td align="left" rowspan="1" colspan="1">62.0/54.0</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">Taqman</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Cotterchio <xref ref-type="bibr" rid="pone.0049134-Cotterchio1">[27]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2008</td>
                  <td align="left" rowspan="1" colspan="1">Canadian</td>
                  <td align="left" rowspan="1" colspan="1">ICD-9</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">834/1249</td>
                  <td align="left" rowspan="1" colspan="1">NA/NA</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">Taqman</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Buyukdogan <xref ref-type="bibr" rid="pone.0049134-Buyukdogan1">[28]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2009</td>
                  <td align="left" rowspan="1" colspan="1">Turkish</td>
                  <td align="left" rowspan="1" colspan="1">CRC patients</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">77/78</td>
                  <td align="left" rowspan="1" colspan="1">52.0/53.0</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">RT-PCR</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Northwood <xref ref-type="bibr" rid="pone.0049134-Northwood1">[29]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2010</td>
                  <td align="left" rowspan="1" colspan="1">British</td>
                  <td align="left" rowspan="1" colspan="1">Colonoscopy confirmed</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">308/296</td>
                  <td align="left" rowspan="1" colspan="1">71.3/58.8</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">Taqman</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Cleary <xref ref-type="bibr" rid="pone.0049134-Cleary1">[30]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2010</td>
                  <td align="left" rowspan="1" colspan="1">Canadian</td>
                  <td align="left" rowspan="1" colspan="1">ICD-9</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">1165/1292</td>
                  <td align="left" rowspan="1" colspan="1">41.0/56.0</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">Taqman</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Sainz <xref ref-type="bibr" rid="pone.0049134-Sainz1">[31]</xref></td>
                  <td align="left" rowspan="1" colspan="1">2011</td>
                  <td align="left" rowspan="1" colspan="1">German</td>
                  <td align="left" rowspan="1" colspan="1">CRC patients</td>
                  <td align="left" rowspan="1" colspan="1">Healthy</td>
                  <td align="left" rowspan="1" colspan="1">1768/1783</td>
                  <td align="left" rowspan="1" colspan="1">58.6/59.8</td>
                  <td align="left" rowspan="1" colspan="1">PB</td>
                  <td align="left" rowspan="1" colspan="1">KASPar assay</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt101">
              <p>ICD: International Classification of Diseases, NA: not available, HB: hospital-based, PB: population-based.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="s3b">
        <title>Association of R144C Polymorphism with CRC</title>
        <p>Overall, there was no evidence of an association between the increased risk of CRC and the R144C variant in different genetic models when all eligible studies were pooled into the meta-analysis. Using random effect model, the per-allele overall OR of the C variant for CRC was 0.98 [95% CI: 0.89−1.06; <italic>P</italic>(Z) = 0.58; <italic>P</italic>(Q) = 0.04], with corresponding results under dominant and recessive genetic models of 0.94 [95% CI: 0.85−1.04; <italic>P</italic>(Z) = 0.21; <italic>P</italic>(Q) = 0.05, <xref ref-type="fig" rid="pone-0049134-g002">Figure 2</xref>] and 1.22 [95% CI: 1.00−1.47; <italic>P</italic>(Z) = 0.05; <italic>P</italic>(Q) = 0.46], respectively.</p>
        <fig id="pone-0049134-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0049134.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Forest plot from the meta-analysis of colorectal cancer and CYP2C9 R144C polymorphism using dominant genetic model.</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0049134.g002" position="float" xlink:type="simple"/>
        </fig>
        <p>Analysis restricted to the 12 studies conducted in Caucasian population (total, 9077 cases and 10822 controls), yielded an per-allele OR for C variant of 0.98 [95% CI: 0.90−1.07; <italic>P</italic>(Z) = 0.16; <italic>P</italic>(Q) = 0.09]. Similar results were also found using dominant [OR = 0.94, 95% CI: 0.86−1.04; <italic>P</italic>(Z) = 0.25; <italic>P</italic>(Q) = 0.04] or recessive [OR = 1.24, 95% CI: 1.00−1.52; <italic>P</italic>(Z) = 0.05; <italic>P</italic>(Q) = 0.39] genetic model. The polymorphism was found to occur in frequencies consistent with HWE in the control populations for these studies.</p>
        <p>The data on genotypes of the polymorphism among cases stratified by the sex were available in 5 studies. The per-allele OR was 1.06 [95% CI: 0.75−1.50; <italic>P</italic>(Z) = 0.73; <italic>P</italic>(Q) = 0.02] in woman compared to 0.91 [95% CI: 0.71−1.17; <italic>P</italic>(Z) = 0.45; <italic>P</italic>(Q) = 0.15] in men. Similarly, no statistically significant results were observed under dominant and recessive genetic models.</p>
      </sec>
      <sec id="s3c">
        <title>Association of I359L Polymorphism with CRC</title>
        <p>Overall, the per-allele OR of the I359L polymorphism for CRC was 0.99 [95% CI: 0.87−1.14; <italic>P</italic>(Z) = 0.94; <italic>P</italic>(Q) = 0.03], with corresponding results under dominant and recessive genetic models of 1.00 [95% CI: 0.86−1.16; <italic>P</italic>(Z) = 0.97; <italic>P</italic>(Q) = 0.02, <xref ref-type="fig" rid="pone-0049134-g003">Figure 3</xref>] and 0.87 [95% CI: 0.41−1.88; <italic>P</italic>(Z) = 0.73; <italic>P</italic>(Q) = 0.21], respectively. One study founded to be deviated from HWE, negative results still maintained after excluding it [L allele: OR = 1.02, 95%CI = 0.90−1.16, <italic>P</italic>(Z) = 0.75, <italic>P</italic>(Q) = 0.07; dominant model: OR = 1.03, 95% CI = 0.89−1.18, <italic>P</italic>(Z) = 0.70, <italic>P</italic>(Q) = 0.05; recessive model: OR = 0.87, 95% CI = 0.40−1.88, <italic>P</italic>(Z) = 0.73, <italic>P</italic>(Q) = 0.21].</p>
        <fig id="pone-0049134-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0049134.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Forest plot from the meta-analysis of colorectal cancer and CYP2C9 I359L polymorphism using dominant genetic model.</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0049134.g003" position="float" xlink:type="simple"/>
        </fig>
        <p>The meta-analysis included 11 studies (7,374 cases and 8,734 controls) in Caucasian population. The Q-test of heterogeneity was not significant in the contrasts of L versus I, dominant, and recessive genetic models. No statistically significant association was established for the CYP2C9 I359L polymorphism in Caucasian population (L allele: OR = 0.95, 95% CI = 0.87−1.05, <italic>P</italic> = 0.33; dominant model: OR = 0.96, 95% CI = 0.86−1.06, <italic>P</italic> = 0.40; recessive model: OR = 0.87, 95% CI = 0.40−1.88, <italic>P</italic> = 0.73).</p>
        <p>When studies were stratified for sex (6 studies), no significant risks were found among men in all genetic models [L allele: OR = 1.22, 95% CI = 0.66−2.28, <italic>P</italic>(Z) = 0.54; dominant model: OR = 1.24, 95% CI = 0.64−2.41, <italic>P</italic>(Z) = 0.52; recessive model: OR = 0.69, 95% CI = 0.11−4.11, <italic>P</italic>(Z) = 0.68]. Similar results were also found in the woman [L allele: OR = 1.21, 95% CI = 0.94−1.57, <italic>P</italic>(Z) = 0.14; dominant model: OR = 1.22, 95% CI = 0.92−1.60, <italic>P</italic>(Z) = 0.16; recessive model: OR = 2.03, 95% CI = 0.51−8.15, <italic>P</italic>(Z) = 0.32].</p>
      </sec>
      <sec id="s3d">
        <title>Sensitivity Analyses and Publication Bias</title>
        <p>A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual dataset to the pooled ORs, and the corresponding pooled ORs were not qualitatively altered (data not shown). Begg’s funnel plot and Egger’s test were performed to access the publication bias of the literatures. The shape of the funnel plots was symmetrical for the two polymorphisms (<xref ref-type="supplementary-material" rid="pone.0049134.s001">Figure S1</xref> and <xref ref-type="supplementary-material" rid="pone.0049134.s002">S2</xref>). The statistical results still did not show publication bias in these studies for R144C (Egger’s test: <italic>P</italic> = 0.86) and I359L (Egger’s test: <italic>P</italic> = 0.97).</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <p>Large sample and unbiased epidemiological studies of predisposition genes polymorphisms could provide insight into the in vivo relationship between candidate genes and complex diseases. The involvement of CYP2C9 enzyme in the metabolism of xenobiotics could underlie the mechanism responsible for the association of CYP2C9 genotype and colorectal cancer. So far, many studies had focused on association between CYP2C9 polymorphism and CRC, but the results were still unclear. This is the first comprehensive meta-analysis examined the two functional polymorphism (R144C and I359L) of CYP2C9 and the relationship to susceptibility for CRC. Its strength was based on the accumulation of published data giving greater information to detect significant differences. In total, the meta-analysis involved 14 studies for CRC which provided 9,463 cases and 11,416 controls.</p>
      <p>In this large-scale meta-analysis, the combined evidence suggested that CYP2C9 *2 and *3 polymorphism did not contribute to the development of CRC. However, CRC is a complex disease, and both environmental and genetic factors are involved in the development of CRC. There are some possible reasons for the inconsistent results in early reports. Firstly, ethnic differences may attribute to these different results, since the distributions of the CYP2C9 polymorphism were different between various ethnic populations. For instance, the frequencies of CYP2C9*2 polymorphism allele differs from 0.6% in Chinese population <xref ref-type="bibr" rid="pone.0049134-Xiong1">[32]</xref>, 11% in British populations <xref ref-type="bibr" rid="pone.0049134-Northwood1">[29]</xref>, to 18% in Caucasian-American <xref ref-type="bibr" rid="pone.0049134-Tranah1">[21]</xref>. On the other hand, study design or small sample size or some environmental factors may affect the results. Most of these studies did not consider most of the important environmental factors. It is possible that variation at this locus has modest effects on CRC, but environmental factors may predominate in the progress of CRC, and mask the effects of this variation. Specific environmental factors like lifestyle and cigarette smoking have already been well studied in recent decades <xref ref-type="bibr" rid="pone.0049134-Tranah1">[21]</xref>, <xref ref-type="bibr" rid="pone.0049134-Kry1">[26]</xref>. The unconsidered factors mixed together may cover the role of <italic>CYP2C9</italic> polymorphism. Thus, even if the variation has a causal effect on CRC, it may take a long time to be observed.</p>
      <p>CYP2C9*3 encodes a protein with approximately 5–30% of the activity of the common reference allele <xref ref-type="bibr" rid="pone.0049134-Takahashi1">[33]</xref>, and it could therefore be hypothesized that CYP2C9*3 allele carriers have reduced carcinogen activating ability and thus reduced disease risk. However, the increased CRC risk associated with CYP2C9*2 genotype in earlier studies suggests that the enzyme may play a more important role in detoxification of carcinogens. The CYP2C9*3 association data should therefore be considered as a hypothesis-generating observation, which requires replication in larger independent cohorts. We also acknowledge that our study is not sufficiently powered to investigate the influence of low frequency alleles such as CYP2C9*3 (few CYP2C9*3/*3 homozygotes were present in our study) even by pooling all available data together. It is also important to note that CYP2C9, like many other P450 enzymes is inducible by a variety of structurally diverse chemicals, as part of the body’s adaptive response to environmental challenge <xref ref-type="bibr" rid="pone.0049134-Zhou1">[34]</xref>. It will therefore be of interest in future studies to investigate the extent of individuality in CYP2C9 protein expression and activity (and the expression of other inducible drug metabolizing enzymes), to assess the extent to which CYP2C9 phenotype influences CRC risk.</p>
      <p>In interpreting the results, some limitations of this meta-analysis should be addressed. Firstly, our results were based on unadjusted estimates, while a more precise analysis should be conducted if all individual raw data were available, which would allow for the adjustment by other co-variants including age, drinking status, cigarette consumption, and other lifestyle. Secondly, the subgroup meta-analyses considering sex different between CYP2C9 polymorphisms and CRC risk, was performed on the basis of a fraction of all the possible data to be pooled, so selection bias may have occurred and our results may be overinflated. Nevertheless, the total number of subjects included in this part of the analysis comprises the largest sample size so far. Thirdly, only published studies were included in this meta-analysis. Therefore, publication bias may have occurred, even though the use of a statistical test did not show it.</p>
      <p>To conclude, our meta-analysis did not support an association of the R144C and I359L polymorphism of CYP2C9 with CRC. The importance of these polymorphisms as a predictor of the risk of CRC is probably very small and the screening utility of this genetic variant in asymptomatic individuals may not be warranted. It is also known that the pathogenesis of CRC is complex and polygenetic in the vast majority of patients, with several genes, each with a small to moderate effect, acting individually, together or in association with important environmental determinants. Larger studies of different ethnic populations, especially strict selection of patients, well-matched controls, are needed to confirm our findings.</p>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pone.0049134.s001" mimetype="image/tiff" xlink:href="info:doi/10.1371/journal.pone.0049134.s001" position="float" xlink:type="simple">
        <label>Figure S1</label>
        <caption>
          <p>Begg’s funnel plot of CYP2C9 R144C polymorphism and colorectal cancer.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0049134.s002" mimetype="image/tiff" xlink:href="info:doi/10.1371/journal.pone.0049134.s002" position="float" xlink:type="simple">
        <label>Figure S2</label>
        <caption>
          <p>Begg’s funnel plot of CYP2C9 I359L polymorphism and colorectal cancer.</p>
          <p>(TIF)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0049134.s003" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0049134.s003" position="float" xlink:type="simple">
        <label>Checklist S1</label>
        <caption>
          <p>(DOC)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pone.0049134-Center1">
        <label>1</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">Center MM, Jemal A, Smith RA, Ward E</collab> (<year>2009</year>) <article-title>Worldwide variations in colorectal cancer</article-title>. <source>CA Cancer J Clin</source> <volume>59</volume>: <fpage>366</fpage>–<lpage>378</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Gertig1">
        <label>2</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gertig</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>DJ</given-names></name> (<year>1998</year>) <article-title>Genes and environment in the etiology of colorectal cancer</article-title>. <source>Semin Cancer Biol</source> <volume>8</volume>: <fpage>285</fpage>–<lpage>298</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Marchand1">
        <label>3</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marchand</surname><given-names>LL</given-names></name> (<year>1999</year>) <article-title>Combined influence of genetic and dietary factors on colorectal cancer incidence in Japanese Americans</article-title>. <source>J Natl Cancer Inst Monogr</source> <volume>26</volume>: <fpage>101</fpage>–<lpage>105</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Lafuente1">
        <label>4</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lafuente</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Casterad</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Trias</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>NAD(P)H:quinone oxidor-eductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors</article-title>. <source>Carcinogenesis</source> <volume>21</volume>: <fpage>1813</fpage>–<lpage>1819</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Windmill1">
        <label>5</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Windmill</surname><given-names>KF</given-names></name>, <name name-style="western"><surname>McKinnon</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Gaedigk</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>McManus</surname><given-names>ME</given-names></name> (<year>1997</year>) <article-title>The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies</article-title>. <source>Mutat Res</source> <volume>376</volume>: <fpage>153</fpage>–<lpage>160</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Ilett1">
        <label>6</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ilett</surname><given-names>KF</given-names></name>, <name name-style="western"><surname>Ingram</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Carpenter</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Teitel</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Kadlubar</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Minchin</surname><given-names>RF</given-names></name> (<year>1994</year>) <article-title>Expression of monomorphic and polymorphic <italic>N</italic>-acetyltransferases in human colon</article-title>. <source>Biochem Pharmacol</source> <volume>47</volume>: <fpage>914</fpage>–<lpage>917</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Goldstein1">
        <label>7</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goldstein</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>De Morais</surname><given-names>SM</given-names></name> (<year>1994</year>) <article-title>Biochemistry and molecular biology of the human CYP2C subfamily</article-title>. <source>Pharmacogenetics</source> <volume>4</volume>: <fpage>285</fpage>–<lpage>299</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Inoue1">
        <label>8</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Inoue</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamakazi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Imiya</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Akasaka</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Guengerich</surname><given-names>FP</given-names></name>, <name name-style="western"><surname>Shimada</surname><given-names>T</given-names></name> (<year>1997</year>) <article-title>Relationship between <italic>CYP2C9</italic> and <italic>CYP2C19</italic> genotypes and tolbutamide methyl hydroxylation and <italic>S</italic>-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations</article-title>. <source>Pharmacogenetics</source> <volume>7</volume>: <fpage>103</fpage>–<lpage>113</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Tang1">
        <label>9</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Shou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mei</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Rushmore</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Rodrigues</surname><given-names>AD</given-names></name> (<year>2000</year>) <article-title>Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor</article-title>. <source>J Pharmacol Exp Ther</source> <volume>293</volume>: <fpage>453</fpage>–<lpage>459</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Tang2">
        <label>10</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Shou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rodrigues</surname><given-names>AD</given-names></name> (<year>2000</year>) <article-title>Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity</article-title>. <source>Drug Metab Dispos</source> <volume>28</volume>: <fpage>567</fpage>–<lpage>572</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Tang3">
        <label>11</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Shou</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rushmore</surname><given-names>TH</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: Correlation with CYP2C9 genotype and in-vivo pharmaco-kinetics</article-title>. <source>Pharmacogenetics</source> <volume>11</volume>: <fpage>223</fpage>–<lpage>235</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Sandberg1">
        <label>12</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sandberg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yasar</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Stromberg</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hoog</surname><given-names>JO</given-names></name>, <name name-style="western"><surname>Eliasson</surname><given-names>E</given-names></name> (<year>2002</year>) <article-title>Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase</article-title>. <source>Br J Clin Pharmacol</source> <volume>54</volume>: <fpage>423</fpage>–<lpage>429</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Takanashi1">
        <label>13</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takanashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tainaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yasumori</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hosakawa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chiba</surname><given-names>K</given-names></name> (<year>2000</year>) <article-title>CYP2C9 Ile359 and Leu359 variants: Enzyme kinetic study with seven substrates</article-title>. <source>Pharmacogenetics</source> <volume>10</volume>: <fpage>95</fpage>–<lpage>104</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Crespi1">
        <label>14</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Crespi</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>VP</given-names></name> (<year>1997</year>) <article-title>The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: Cytochrome P450 oxidoreductase</article-title>. <source>Pharmacogenetics</source> <volume>7</volume>: <fpage>203</fpage>–<lpage>210</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-DerSimonian1">
        <label>15</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname><given-names>N</given-names></name> (<year>1986</year>) <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Woolf1">
        <label>16</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Woolf</surname><given-names>B</given-names></name> (<year>1955</year>) <article-title>On estimating the relation between blood group and disease</article-title>. <source>Ann Hum Genet</source> <volume>19</volume>: <fpage>251</fpage>–<lpage>253</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Egger1">
        <label>17</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname><given-names>C</given-names></name> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Begg1">
        <label>18</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>101</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Martinez1">
        <label>19</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Martinez</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Garcia-Martin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ladero</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Sastre</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Garcia-Gamito</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk</article-title>. <source>Carcinogenesis</source> <volume>22</volume>: <fpage>1323</fpage>–<lpage>1326</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Chan1">
        <label>20</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Tranah</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Giovannucci</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Fuchs</surname><given-names>CS</given-names></name> (<year>2004</year>) <article-title>A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma</article-title>. <source>Clin Gastroenterol Hepatol</source> <volume>2</volume>: <fpage>704</fpage>–<lpage>712</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Tranah1">
        <label>21</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tranah</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Giovannucci</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fuchs</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses’ Health Study and the Physicians’ Health Study</article-title>. <source>Mol Carcinog</source> <volume>44</volume>: <fpage>21</fpage>–<lpage>30</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Landi1">
        <label>22</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Landi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gemignani</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Gioia-Patricola</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chabrier</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer</article-title>. <source>Pharmacogenet Genomics</source> <volume>15</volume>: <fpage>535</fpage>–<lpage>546</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-McGreavey1">
        <label>23</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McGreavey</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Boylan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Timothy Bishop</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma</article-title>. <source>Pharmacogenet Genomics</source> <volume>15</volume>: <fpage>713</fpage>–<lpage>721</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Samowitz1">
        <label>24</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Samowitz</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Wolff</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Curtin</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sweeney</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>KN</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention</article-title>. <source>Clin Gastroenterol Hepatol</source> <volume>4</volume>: <fpage>894</fpage>–<lpage>901</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Liao1">
        <label>25</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liao</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>AK</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese</article-title>. <source>Clin Chim Acta</source> <volume>380</volume>: <fpage>191</fpage>–<lpage>196</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Kry1">
        <label>26</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Küry</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Buecher</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Robiou-du-Pont</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Scoul</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sebille</surname><given-names>V</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>16</volume>: <fpage>1460</fpage>–<lpage>1467</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Cotterchio1">
        <label>27</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cotterchio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Boucher</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Manno</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gallinger</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Okey</surname><given-names>AB</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>17</volume>: <fpage>3098</fpage>–<lpage>3107</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Buyukdogan1">
        <label>28</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Buyukdogan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Boruban</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Artac</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Demirel</surname><given-names>S</given-names></name> (<year>2009</year>) <article-title>Frequency of Cytochrome 450 (CYP2C9 and CYP2C19) genetic polimorphisms in patients with colorectal carcinoma</article-title>. <source>Int J Hemato Oncol</source> <volume>19</volume>: <fpage>134</fpage>–<lpage>139</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Northwood1">
        <label>29</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Northwood</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Elliott</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Forman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Barrett</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Wilkie</surname><given-names>MJ</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk</article-title>. <source>Pharmacogenet Genomics</source> <volume>20</volume>: <fpage>315</fpage>–<lpage>326</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Cleary1">
        <label>30</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cleary</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Cotterchio</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gallinger</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Harper</surname><given-names>P</given-names></name> (<year>2010</year>) <article-title>Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk</article-title>. <source>Am J Epidemiol</source> <volume>172</volume>: <fpage>1000</fpage>–<lpage>1014</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Sainz1">
        <label>31</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sainz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rudolph</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hein</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hoffmeister</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Buch</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk</article-title>. <source>Endocr Relat Cancer</source> <volume>18</volume>: <fpage>265</fpage>–<lpage>276</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Xiong1">
        <label>32</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xiong</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Xing</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>He</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>S</given-names></name> (<year>2011</year>) <article-title>A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China</article-title>. <source>Genomics</source> <volume>97</volume>: <fpage>277</fpage>–<lpage>281</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Takahashi1">
        <label>33</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kashima</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nomoto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Iwade</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tainaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shimizu</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes</article-title>. <source>Pharmacogenetics</source> <volume>8</volume>: <fpage>365</fpage>–<lpage>373</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0049134-Zhou1">
        <label>34</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhou</surname><given-names>SF</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>ZW</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>LP</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>JP</given-names></name> (<year>2009</year>) <article-title>Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development</article-title>. <source>Curr Med Chem</source> <volume>16</volume>: <fpage>3480</fpage>–<lpage>3675</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>